{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-099837","form_type":"8-K","ticker":"RMTG","cik":"0001760026","company_name":"Regenerative Medical Technology Group Inc.","filed_at":"2024-11-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.504524+00:00","generated_at":"2026-05-29T22:34:51.939048+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"RMTG reports Q3 sales up 52% YoY, achieves operational profitability, gross margin 75%","bullets":["Sales rose 52% YoY to $986,308; gross profit margin reached 75% for Q3 2024.","Patient procedures revenue surged over 370% YoY, now 37% of revenue versus 12% last year.","Company achieved operational profitability, defined as revenue minus all operating expenses excluding interest and taxes.","Dubai clinic expected to launch next week; plans for a manufacturing facility in Cancun to produce exosomes and stem cells."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-099837","json":"https://secwatch.observer/filing/0001213900-24-099837.json","markdown":"https://secwatch.observer/filing/0001213900-24-099837.md","text":"https://secwatch.observer/filing/0001213900-24-099837.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760026/000121390024099837/0001213900-24-099837-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760026/000121390024099837/ea0221755-8k_regenerative.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T22:34:51.939048+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}